TxCell is developing innovative, personalized cell immunotherapies using regulatory T-cells (Treg) for severe chronic inflammatory and autoimmune diseases.

The product candidates developed by TxCell and belonging to its first product platform ASTrIA (Antigen-Specific Treg for Inflammation an Autoimmunity) consist of autologous antigen-specific type 1 regulatory T cells (Ag-Tregs) generated ex-vivo from patient's blood in a proprietary manufacturing process (link).

Ovasave® is TxCell lead product candidate derived from TxCell's proprietary platform. A phase IIb placebo controlled study has been initiated in refractory Crohn's Disease patients. This follows a phase I/IIa study in the same patient population, which has been successfully completed and reported positive clinical efficacy and good tolerability (link1 & link2).

Txcell's second product candidate, Col-Treg, is in development for Autoimmune Uveitis, a rare disease with very limited treatment options. The next step in this program will be a first-in-Man clinical trial aiming at demonstrating the safety and exploring the efficacy of Col-Treg in Autoimmune Uveitis patients.

Further product candidates for autoimmune inflammatory indications are in preclinical development.

This platform enables TxCell to consider the development of an important pipeline of products for the treatment of many chronic inflammatory and autoimmune diseases which may constitute a catalyst in the medium and long term for the company through internal developments and / or partnerships.

In addition to its ASTrIA platform, which includes antigen-specific Type 1 Treg cells, TxCell is working on the development of a second product platform ENTrIA (Engineered Tregs in Inflammation and Auto-immunity) based on redirected, genetically engineered T regulatory cells (CAR-Treg) and their use in suppression of autoimmune and inflammatory diseases. This new platform could lead TxCell to develop a new type of products with the ability to deliver their immunomodulatory action independently of antigen presentation via MHC molecules and express on their surface chimeric antigen receptor (CAR).

Cell therapy products derived from this engineered Treg cells platform could give TxCell the opportunity to meet an even wider spectrum of chronic inflammatory and autoimmune conditions with a strong medical need.

 Conference call and webcast in English: Friday March 11 at 3:30pm CET

 To listen to the replay, please dial: +33 (0)1 72 00 15 00 / 299977#

160311 Update on Activities and FY 2015 Accounts v4 clean

Interview of Stéphane Boissel at Salon Actionnaria, November 20, 2015  
SB photo       

2015 Registration Document (Document de Référence) - 24/05/2016    Corporate Presentation - May 2016 - 26/05/2016
 DDR 2014             Corporate Presentation

Arnaud Foussat, "Assessing regulatory T cells as therapy", MedNous, Vol 9, N° 5, May 2015, 10-11.

  Stéphane Boissel, "The sky is the limit as Cellgene invests in Juno", MedNous, Vol 9, N° 6, July/August 2015, 10-11.
Assessing regulatory T cells as therapy        

MedNousJULY AUG2015 Celgene Juno



April 25-29, 2016
PEGS Summit Boston, Boston, United States


May 18-20, 2016
World Stem Cells & Regenerative Medicines Congress 2016, London, United Kingdom.


May 25-28, 2016
ISCT 2016 Annual Meeting, Singapore


June 28-30, 2016
North American Adoptive T Cell Therapy Congress, Boston, United States